中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

600 records (took 0.038 seconds)

    Use of oxandrolone in the treatment of burns and other wounds
    1.
    发明授权
    Use of oxandrolone in the treatment of burns and other wounds 失效
    用oxandrolone治疗烧伤和其他伤口

    公开(公告)号：US08053425B2

    公开(公告)日：2011-11-08

    申请号：US10799264

    申请日：2004-03-12

    Applicant: Don Fishbein

    Inventor： Don Fishbein

    IPC: A61K31/585 ,  A61K31/35

    CPC classification number: A61K31/366 ,  Y10S514/925 ,  Y10S514/928

    Abstract: The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.

    Abstract translation: 本发明提供了一种治疗烧伤患者的烧伤引起的体重减轻的方法，其包括向患者施用治疗有效量的奥地罗尔酮。 本发明还提供了治疗患有伤口的患者中的伤口的方法，其包括向患者施用治疗有效量的奥地罗尔酮。 本发明进一步提供了一种治疗烧伤患者的烧伤引起的体重减轻的方法，该方法包括与患者的蛋白质补充剂一起施用治疗有效量的奥多罗酮。

    METHOD OF USING LECTINS FOR PREVENTION AND TREATMENT OF ORAL AND ALIMENTARY TRACT DISORDERS
    3.
    发明申请
    METHOD OF USING LECTINS FOR PREVENTION AND TREATMENT OF ORAL AND ALIMENTARY TRACT DISORDERS 失效
    用于预防和治疗口腔和动脉疾病的方法

    公开(公告)号：US20100331242A1

    公开(公告)日：2010-12-30

    申请号：US12875826

    申请日：2010-09-03

    Applicant: HOWARD C. KRIVAN ,  RICHARD C. POTTER ,  MICHAEL J. OLDHAM

    Inventor： HOWARD C. KRIVAN ,  RICHARD C. POTTER ,  MICHAEL J. OLDHAM

    IPC: A61K38/02 ,  A61P31/04 ,  A61P1/04

    CPC classification number: A61K38/17 ,  A61K38/168 ,  Y10S514/925 ,  Y10S514/926 ,  Y10S514/927 ,  Y10S514/928

    Abstract: Infectious diseases caused by pathogenic microorganisms resident in the alimentary tract of humans and animals can be prevented and treated by administering to the alimentary tract of the human or animal an effective amount of a composition containing at least one lectin capable of binding to an infective microorganism and diminishing its infective capability of the microorganism. The lectin is administered dispensed in a pharmaceutically acceptable non-toxic vehicle. Peptic ulcer disease caused by infection with H. pylori can be treated by oral administration of lectins that bind to the pathogen. A beneficial ecology of H. pylori can be maintained in infected patients by chronic oral administration of lectins that bind to the pathogen.

    Abstract translation: 可以通过向人或动物的消化道施用有效量的含有至少一种能够与感染性微生物结合的凝集素的组合物，并且可以防止和处理由存在于人和动物消化道中的致病微生物引起的传染病， 降低微生物的感染能力。 凝集素在药学上可接受的无毒性载体中分配。 可以通过口服施用与病原体结合的凝集素来治疗由幽门螺杆菌感染引起的消化性溃疡病。 通过慢性口服施用与病原体结合的凝集素，可以在感染患者中保持幽门螺杆菌的有益生态。

    Delivery of trefoil peptides
    5.
    发明申请
    Delivery of trefoil peptides 有权

    公开(公告)号：US20070110723A1

    公开(公告)日：2007-05-17

    申请号：US11654985

    申请日：2007-01-18

    Applicant: Wolfgang Hans ,  Lothar Steidler ,  Erik Remaut

    Inventor： Wolfgang Hans ,  Lothar Steidler ,  Erik Remaut

    IPC: A61K48/00

    CPC classification number: C07K14/575 ,  A61K38/00 ,  C07K2319/02 ,  C12N15/746 ,  Y10S514/899 ,  Y10S514/925

    Abstract: The present invention relates to a microorganism, preferably a bacterial strain, preferably a non-pathogenic strain, preferably a non-invasive strain, preferably a food grade strain, preferably a gram-positive bacterial strain, delivering a trefoil peptide in vivo. Preferably said trefoil peptide is TFF1. The present invention further relates to a method for the delivery of trefoil peptide to the gastro-intestinal tract comprising the administration of such a bacterial strain. The present invention also relates to a pharmaceutical composition comprising a trefoil peptide delivering bacterium as well as methods of treatment of acute gastro-intestinal inflammatory diseases comprising administration of said transformed bacterial strains, particularly for treating acute colitis, including but not limited to acute flare-ups of Crohn's disease and ulcerative colitis in humans, as well as for treating gastro-intestinal disorders of a similar nature in other animal species.

    Novel therapeutic uses of glucan
    6.
    发明申请
    Novel therapeutic uses of glucan 失效
    葡聚糖的新型治疗用途

    公开(公告)号：US20060293278A1

    公开(公告)日：2006-12-28

    申请号：US11499534

    申请日：2006-08-04

    Applicant: Graham Kelly

    Inventor： Graham Kelly

    IPC: A61K31/716 ,  C07H1/00

    CPC classification number: A61Q17/04 ,  A61K8/73 ,  A61K31/716 ,  A61L26/0023 ,  A61Q19/004 ,  A61Q19/08 ,  C08B37/0024 ,  C12P19/04 ,  Y10S514/925 ,  Y10S514/928 ,  C08L5/00

    Abstract: A process for the production of β-(1,3)(1,6) glucan from a glucan containing cellular source is described, together with compositions and uses/methods of treatment involving glucan. The process of the invention comprises the steps of: (a) extracting glucan containing cells with alkali and heat, in order to remove alkali soluble components; (b) acid extracting the cells of step (a) with an acid and heat to form a suspension; (c) extracting the suspension obtained of step (b) or recovered hydrolyzed cells with an organic solvent which is non-miscible with water and which has a density greater than that of water separating the resultant aqueous phase, solvent containing phase and interface so that substantially only the aqueous phase comprising β-(1,3)(1,6) glucan particulate material remains; wherein the extraction with said organic solvent provides separation of glucan subgroups comprising branched β-(1,3)(1,6)-glucan, and essentially unbranched β-(1,3) glucan which is associated with residual non-glucan contaminents; and (d) drying the glucan material from step (c) to give microparticulate glucan.

    Abstract translation: 描述了从含葡聚糖的细胞源生产β-（1,3）（1,6）葡聚糖的方法，以及涉及葡聚糖的组合物和用途/治疗方法。 本发明的方法包括以下步骤：（a）用碱和热提取含葡聚糖的细胞，以除去碱溶性组分; （b）用酸和热将酸步骤（a）的细胞萃取以形成悬浮液; （c）用与水不溶的有机溶剂提取步骤（b）获得的悬浮液或回收的水解细胞，其密度大于分离所得水相，含溶剂相和界面的水的密度，使得 基本上只剩下包含β-（1,3）（1,6）葡聚糖颗粒材料的水相; 其中用所述有机溶剂萃取提供葡聚糖亚组的分离，所述葡聚糖亚组包含与残留的非葡聚糖污染物相关的支链β-（1,3）（1,6） - 葡聚糖和基本上未分支的β-（1,3）葡聚糖; 和（d）干燥步骤（c）的葡聚糖材料，得到微粒葡聚糖。

    Polycosanols from Ericerus pela wax
    9.
    发明申请
    Polycosanols from Ericerus pela wax 审中-公开
    来自梨果的聚山梨醇蜡

    公开(公告)号：US20050239904A1

    公开(公告)日：2005-10-27

    申请号：US11157992

    申请日：2005-06-21

    Applicant: Qi Jia ,  Ji-Fu Zhao

    Inventor： Qi Jia ,  Ji-Fu Zhao

    IPC: A61K31/045 ,  A61K35/63 ,  A61K35/64

    CPC classification number: A61K31/045 ,  A61K35/63 ,  Y10S514/925 ,  A61K2300/00

    Abstract: The present invention provides a novel method for the preparation of a unique profile of primary aliphatic alcohols, having 24 to 30 carbon atoms, from the wax secreted by the insect Ericerus pela. Included in the present invention is the composition of matter, referred to herein as “polycosanol” produced by the method of this invention. The polycosanol composition is comprised primarily of the four primary aliphatic alcohols, tetracosanol, hexacosanol, octacosanol and triacontanol. Further included in this invention is the use of said composition of matter for the prevention and treatment of obesity, syndrome X, diabetes, hypercholesterolemia, atherosclerotic complications, ischemia and thrombosis.

    Abstract translation: 本发明提供了一种新颖的方法，用于制备具有24至30个碳原子的伯脂肪醇，其特征在于由昆虫螨属分泌的蜡。 本发明中包括由本发明的方法生产的物质组合物，这里称为“多可醇”。 多糖醇组合物主要由四种脂族醇，二十四烷醇，二十四烷醇，三十烷醇组成。 本发明还包括所述物质组合物用于预防和治疗肥胖症，综合征X，糖尿病，高胆固醇血症，动脉粥样硬化并发症，局部缺血和血栓形成的用途。

Patent Agency Ranking